Thomas F. Burke on Muck Rack

Thomas F. Burke

Baltimore
As seen in: The Washington Post, The Conversation, Science Magazine, Pittsburgh Tribune-Review, American Thinker, Bryan-College Station Eagle, Roanoke Times, Grand Island Independent, Yakima Herald-Republic, Missoulian and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Thomas F.

Contact Thomas F., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Augmenting Real-World Data Through Modeling Key Clinical Trial Eligibility Criteria: An Example of Patients With Non-small-Cell Lung Cancer Treated With Pembrolizumab | JCO Clinical Cancer Informatics

|
By Thomas Jemielita, Thomas F. Burke, Wei Zhou, Kai-Li Liaw
| ascopubs.org
Abstract To compare and characterize baseline characteristics and overall survival (OS) differences by key oncology eligibility criteria for real-world patients from the Flatiron Health database with advanced non–small-cell lung cancer (NSCLC) who received pembrolizumab monotherapy. Real world data (RWD) were from the Flatiron Health advanced NSCLC database and include patients who initiated pembrolizumab monotherapy (first, second, or third line of therapy) by November 30, 2019.
Open in Who Shared Issue with article?

Real-world study of PD-L1 testing patterns and treatment distribution in patients with metastatic non-small-cell lung cancer in Israel

|
By Sarah Moser, Thomas F. Burke, Lior Apter, Ashwini Arunachalam
| Future Medicine Verified
Lung cancer is the most common cancer diagnosed globally and the leading cause of cancer death worldwide [1]. Non-small-cell lung cancer (NSCLC) accounts for approximately 85–90% of all lung cancer with 5-year survival rate of 19% [2]. Until 2014, platinum-based doublet chemotherapy has been the standard of care for metastatic NSCLC (mNSCLC) with only limited survival benefit [3].
Open in Who Shared Issue with article?

Oxygen Blending is Urgently Needed in Resource-Limited Settings

|
By Sreekar Mantena, Thomas F. Burke
| The Journal of Pediatrics Verified
Abbreviations: ROP (Retinopathy of prematurity), BPD (Bronchopulmonary dysplasia), WHO (World Health Organization) Since then, our understanding of oxygen’s physiological effects has evolved considerably. In the 1930s, Dr Julius Hess created an enclosed oxygen chamber to care for premature infants. 2 The early history of oxygen use for premature infants. Pediatrics.
Open in Who Shared Issue with article?
See all 43 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified